EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieVergleichsstudie

Randomized Trial of COBRA PzF Stenting to Reduce the Duration of Triple Therapy: The COBRA-REDUCE Trial

Robert A Byrne iD, Róisín Colleran, J J Coughlan iD, Rajiv Jauhar iD, Luc Maillard iD, Axel De Labriolle, Michael Maeng iD, Charles Croft, Michael Brunner iD, David Leistner, Bernhard Zrenner, Marc Kollum und 12 weitere

Circulation: Cardiovascular Interventions · 2024

DOI: 10.1161/circinterventions.123.013735 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2024. Verfasst von Robert A Byrne und 23 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Institute, Mater Private Network, Dublin, Ireland (R.A.B., R.C., J.J.C.). Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Hemorrhage, Platelet Aggregation Inhibitors, Drug-Eluting Stents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with an indication for oral anticoagulation who undergo percutaneous coronary intervention require a combination of oral anticoagulation and antiplatelet therapy. The use of a coronary stent with a thromboresistant and pro-healing coating may allow an abbreviated duration of dual antiplatelet therapy (DAPT) without an increase in the risk of thromboembolic events. METHODS: Patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention were randomized to treatment with the COBRA polyzene F (PzF) stent followed by 14 days of DAPT or a Food and Drug Administration–approved new-generation drug-eluting stent followed by 3 or 6 months of DAPT. The bleeding coprimary end point was Bleeding Academic Research Consortium type ≥2 beyond 14 days (or after hospital discharge) until 6 months. The thromboembolic coprimary end point was the composite of all-cause death, myocardial infarction, definite or probable stent thrombosis, or ischemic stroke at 6 months. The trial hypothesis was that the COBRA PzF stent strategy would be superior with respect to bleeding events and noninferior with respect to thromboembolic events. RESULTS: A total of 996 patients underwent randomization. The bleeding end point occurred in 37 of 475 patients (7.8%) in the COBRA PzF group and 47 of 482 patients (9.8%) in the control group (difference, −2.0 [95% CI, −5.6 to 1.6]; P =0.14). The thromboembolic end point occurred in 37 of 492 patients (7.5%) in the COBRA PzF group and 24 of 490 patients (4.9%) in the control group (difference, 2.6%; prespecified noninferiority margin 5%, upper limit of 1-sided 95% CI of the difference, 5.2%; P noninferiority =0.07). CONCLUSIONS: In patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention, treatment with the COBRA PzF stent plus 14 days of DAPT was not superior with respect to bleeding events and was not noninferior with respect to thromboembolic events at 6 months compared with treatment with standard Food and Drug Administration–approved drug-eluting stent plus 3 to 6 months of DAPT. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02594501.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionHemorrhagePlatelet Aggregation InhibitorsDrug-Eluting StentsAnticoagulantsCoronary Artery DiseaseProsthesis DesignDrug Administration ScheduleHumansMaleFemaleAgedTime FactorsMiddle AgedTreatment OutcomeRisk FactorsAdministration, OralThromboembolismDrug Therapy, CombinationDual Anti-Platelet TherapyCoronary ThrombosisRisk AssessmentProspective StudiesStents

Stichwörter der Autor:innen

anticoagulantsdrug-eluting stentspercutaneous coronary interventionplatelet aggregation inhibitorsstents

Substanzen

Platelet Aggregation InhibitorsAnticoagulants

Autor:innen und Institutionen

  • Cardiovascular Research Institute, Mater Private Network, Dublin, Ireland (R.A.B., R.C., J.J.C.).
  • School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin (R.A.B., R.C., J.J.C.).
  • North Shore University Hospital, Manhasset, NY (R.J.).
  • Department of Cardiology, Groupement de Coopération Sanitaire Axium Rambot, Aix-en-Provence, France (L.M.).
  • Clinique du Pont de Chaume, Montauban, France (A.D.L.).
  • Department of Cardiology, Aarhus University Hospital, Denmark (M.M.).

ORCID-Profile: Robert A Byrne, J J Coughlan, Rajiv Jauhar, Luc Maillard, Michael Maeng, Michael Brunner, Karl-Ludwig Laugwitz, Erion Xhepa, Michael Joner, Ajay Kirtane, Roxana Mehran, Donald E Cutlip, Adnan Kastrati

Zitieren

APA

Byrne, R. A., Colleran, R., Coughlan, J. J., Jauhar, R., Maillard, L., De Labriolle, A., Maeng, M., Croft, C., Brunner, M., Leistner, D., Zrenner, B., Kollum, M., Laugwitz, K. L., Xhepa, E., Mayer, K., Lahu, S., Joner, M., Kirtane, A., Mehran, R., …, & COBRA-REDUCE Investigators (2024). Randomized Trial of COBRA PzF Stenting to Reduce the Duration of Triple Therapy: The COBRA-REDUCE Trial. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.123.013735

Vancouver

Byrne RA, Colleran R, Coughlan JJ, Jauhar R, Maillard L, De Labriolle A, et al. Randomized Trial of COBRA PzF Stenting to Reduce the Duration of Triple Therapy: The COBRA-REDUCE Trial. Circulation: Cardiovascular Interventions. 2024. doi:10.1161/circinterventions.123.013735

BibTeX
@article{Byrne2024,
  author = {Byrne, Robert A and Colleran, Róisín and Coughlan, J J and Jauhar, Rajiv and Maillard, Luc and De Labriolle, Axel and Maeng, Michael and Croft, Charles and Brunner, Michael and Leistner, David and Zrenner, Bernhard and Kollum, Marc and Laugwitz, Karl-Ludwig and Xhepa, Erion and Mayer, Katharina and Lahu, Shqipdona and Joner, Michael and Kirtane, Ajay and Mehran, Roxana and Barakat, Mark and Urban, Philip and Cutlip, Donald E and Kastrati, Adnan and COBRA-REDUCE Investigators, COBRA-REDUCE Investigators},
  title = {Randomized Trial of COBRA PzF Stenting to Reduce the Duration of Triple Therapy: The COBRA-REDUCE Trial},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2024},
  doi = {10.1161/circinterventions.123.013735}
}
Kostenlos starten →